UWM
AQST icon

USAdvisors Wealth Management’s Aquestive Therapeutics AQST Stock Holding History

USAdvisors Wealth Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$33K – 135
2025
Q2 		$33K Buy
+10,000
New +$28.7K 0.01% 133

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

USAdvisors Wealth Management's AQST Position: Q3 2025 in Review

USAdvisors Wealth Management sold out of Aquestive Therapeutics (AQST) in Q3 2025, closing a stake of 10,000 shares — an estimated $33K sold.

USAdvisors Wealth Management first reported a position in AQST in Q2 2025 and held it in 1 quarter. The position peaked at $33K in Q2 2025. 152 funds tracked by Wall St. Rank hold AQST as of Q3 2025.

  • USAdvisors Wealth Management reported no remaining Aquestive Therapeutics position as of Q3 2025 after selling out during the quarter.
  • USAdvisors Wealth Management sold 10,000 Aquestive Therapeutics shares in Q3 2025, an estimated $33K.
  • USAdvisors Wealth Management first reported a position in Aquestive Therapeutics in Q2 2025 and held it in 1 quarter.
  • USAdvisors Wealth Management's Aquestive Therapeutics position peaked at $33K in Q2 2025.
  • 152 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2025.

Based on USAdvisors Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.